Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis

Table 3 Summary of analysis of antropometric data

	L0	L6m	P (L0-6 m)	L12m	P (L0–12 m)	L+T0	L+T6m	P (L+T0–6 m)	L+T12m	P (L+T0–12 m)
Weight	61.48	63.98	0.004	61.03	0.007 ^a	58.65	61.18	0.023	65.10	0.001
SD	0.16	0.36	0.120	0.01	0.911	−0.38	−0.13	0.016	0.01	0.001
BMI	22.58	23.00	0.031	22.39	0.193 ^b	20.69	22.38	0.003	23.26	0.004
SD	0.21	0.43	0.098	0.18	0.719	−0.34	0.20	0.011	0.24	0.004

SD standard deviation in comparison with Flemish peers [27], L0 mean values before initiation of L, L6m mean values after 6 months of L; P(L0–6 m) P values of comparison of baseline parameters with values after 6 months of L, L12m mean values after 12 months of L, P(L0–12 m) P values of comparison of baseline parameters with values after 12 months of L, L+T0 mean values before initiation of L+T, L+T6m mean values after 6 months of L+T, P(L+T0–6 m) P values of comparison of baseline parameters with values after 6 months of L+T, L+T12m mean values after 12 months of L+T, P(L+T0–12 m) P values of comparison of baseline parameters with values after 12 months of L+T, L lynestrenol monotherapy, L+T lynestrenol and testosterone esters combination therapy
^aAlthough mean weight of all patients seems to decrease, a significant increase in weight was noted when comparing weight at baseline with weight after 12 months of L. This discrepancy is caused by exclusion of patients, who had not yet reached 12 months of L at time of analysis
^bBMI non-significantly increased after 12 months of L, although mean BMI seems to decrease. This is due by the same phenomenon as described in a

ISSN: 2042-6410